JP2026502231A - 補体因子ｂ阻害剤、その医薬組成物および使用 - Google Patents

補体因子ｂ阻害剤、その医薬組成物および使用

Info

Publication number
JP2026502231A
JP2026502231A JP2025538315A JP2025538315A JP2026502231A JP 2026502231 A JP2026502231 A JP 2026502231A JP 2025538315 A JP2025538315 A JP 2025538315A JP 2025538315 A JP2025538315 A JP 2025538315A JP 2026502231 A JP2026502231 A JP 2026502231A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
optionally substituted
cycloalkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025538315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026502231A5 (enExample
Inventor
グ，チェンソン
ジ，ファンヤン
シャオ，シュンジエ
チョウ，ユアン
チェン，ジァオシァン
シュ，メンヤン
バイ，ルー
ルオ，ジエ
ファン，レイ
チェン，ビン
ワン，シャオヘイ
チァン，ペイユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of JP2026502231A publication Critical patent/JP2026502231A/ja
Publication of JP2026502231A5 publication Critical patent/JP2026502231A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2025538315A 2022-12-31 2023-12-29 補体因子ｂ阻害剤、その医薬組成物および使用 Pending JP2026502231A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202211737515.0 2022-12-31
CN202211737515 2022-12-31
CN202310699631.6 2023-06-13
CN202310699631 2023-06-13
PCT/CN2023/143205 WO2024141011A1 (zh) 2022-12-31 2023-12-29 补体因子b抑制剂及其药物组合物和应用

Publications (2)

Publication Number Publication Date
JP2026502231A true JP2026502231A (ja) 2026-01-21
JP2026502231A5 JP2026502231A5 (enExample) 2026-05-08

Family

ID=91716537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025538315A Pending JP2026502231A (ja) 2022-12-31 2023-12-29 補体因子ｂ阻害剤、その医薬組成物および使用

Country Status (3)

Country Link
JP (1) JP2026502231A (enExample)
CN (1) CN120435467A (enExample)
WO (1) WO2024141011A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140027090A (ko) * 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
JP6180514B2 (ja) * 2012-05-04 2017-08-16 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
BR112020003737A2 (pt) * 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
US20230286947A1 (en) * 2020-08-07 2023-09-14 Shanghai Meiyue Biotech Development Co. Ltd Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof

Also Published As

Publication number Publication date
WO2024141011A1 (zh) 2024-07-04
CN120435467A (zh) 2025-08-05

Similar Documents

Publication Publication Date Title
JP7642098B2 (ja) カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物
EP3538526B1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
CN113072542B (zh) RORγt抑制剂及其制备方法和用途
TW202311260A (zh) 含有亞磺醯亞胺基的atr抑制劑化合物
US11292799B2 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
CN104822680A (zh) 咪唑并吡啶化合物
CA2922532A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
WO2020042995A1 (zh) 一种高活性sting蛋白激动剂化合物
CN117715906A (zh) 胰高血糖素样肽-1受体调节剂及其用途
UA126829C2 (uk) Піперидиніл-3-(арилокси)пропанаміди та пропаноати
EP4168395B1 (en) Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway
JP2026503035A (ja) 新規な可逆性ｄｐｐ１阻害剤及びその用途
US20240316034A1 (en) Chemokine CXCR4 Receptor Modulators and Uses Related Thereto
TW202333663A (zh) Rxfp1促效劑
CN115066423B (zh) Pd-l1拮抗剂化合物
CN120435467A (zh) 补体因子b抑制剂及其药物组合物和应用
JP6463362B2 (ja) ＲＯＲ−ガンマ阻害剤としてのテトラヒドロ−テトラゾロ［１，５−ａ］ピラジン
JP7627269B2 (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
TW202304906A (zh) 高活性hpk1激酶抑制劑
TW202216664A (zh) 氧代吡咯啶fpr2促效劑
TWI810547B (zh) Pd-l1拮抗劑化合物
WO2026002007A1 (zh) 补体因子b抑制剂及其药物组合物和应用
CA3152485A1 (en) Azepane derivative
JP2009517483A (ja) 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体
TW202542125A (zh) 烯烴類化合物、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424